Infectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United States of America.
PLoS One. 2020 May 29;15(5):e0233893. doi: 10.1371/journal.pone.0233893. eCollection 2020.
A considerable challenge in quantification of the antimalarial piperaquine in plasma is carryover of analyte signal between assays. Current intensive pharmacokinetic studies often rely on the merging of venous and capillary sampling. Drug levels in capillary plasma may be different from those in venous plasma, Thus, correlation between capillary and venous drug levels needs to be established.
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used to develop the method. Piperaquine was measured in 205 pairs of capillary and venous plasma samples collected simultaneously at ≥24hr post dose in children, pregnant women and non-pregnant women receiving dihydroartemisinin-piperaquine as malaria chemoprevention. Standard three-dose regimen over three days applied to all participants with three 40mg dihydroartemisinin/320mg PQ tablets per dose for adults and weight-based dose for children. Correlation analysis was performed using the program Stata® SE12.1. Linear regression models were built using concentrations or logarithm transformed concentrations and the final models were selected based on maximal coefficient of determination (R2) and visual check.
An LC-MS/MS method was developed and validated, utilizing methanol as a protein precipitation agent, a Gemini C18 column (50x2.0mm, 5μm) eluted with basic mobile phase solvents (ammonium hydroxide as the additive), and ESI+ as the ion source. This method had a calibration range of 10-1000 ng/mL and carryover was negligible. Correlation analysis revealed a linear relationship: Ccap = 1.04×Cven+4.20 (R2 = 0.832) without transformation of data, and lnCcap = 1.01×lnCven+0.0125, (R2 = 0.945) with natural logarithm transformation. The mean ratio (±SD) of Ccap/Cven was 1.13±0.42, and median (IQR) was 1.08 (0.917, 1.33).
Capillary and venous plasma PQ measures are nearly identical overall, but not readily exchangeable due to large variation. Further correlation study accounting for disposition phases may be necessary.
在血浆中定量抗疟药哌喹时,一个相当大的挑战是分析物信号在分析之间的残留。目前的强化药代动力学研究通常依赖于静脉和毛细血管采样的合并。毛细血管血浆中的药物水平可能与静脉血浆中的药物水平不同,因此,需要建立毛细血管和静脉药物水平之间的相关性。
采用液相色谱-串联质谱(LC-MS/MS)法建立方法。在接受二氢青蒿素-哌喹作为疟疾化学预防的儿童、孕妇和非孕妇中,在给药后 24 小时以上采集 205 对同时采集的毛细血管和静脉血浆样本,用 LC-MS/MS 测定哌喹。所有参与者均采用标准三剂量方案,每日三次,成人每次 40mg 双氢青蒿素/320mg PQ 片,儿童按体重给药。使用 Stata® SE12.1 程序进行相关分析。使用浓度或对数转换浓度建立线性回归模型,根据最大决定系数(R2)和视觉检查选择最终模型。
建立并验证了一种 LC-MS/MS 方法,使用甲醇作为蛋白沉淀剂,Gemini C18 柱(50x2.0mm,5μm),用碱性流动相溶剂(添加氨)洗脱,并采用 ESI+作为离子源。该方法的校准范围为 10-1000ng/ml,无残留。相关分析显示,未经数据转换时,Ccap=1.04×Cven+4.20(R2=0.832),对数转换后,lnCcap=1.01×lnCven+0.0125,(R2=0.945)。Ccap/Cven 的平均比值(±SD)为 1.13±0.42,中位数(IQR)为 1.08(0.917,1.33)。
总体而言,毛细血管和静脉血浆中的 PQ 测量值非常相似,但由于变异较大,两者不能轻易互换。可能需要进一步研究,考虑处置阶段的相关性。